These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26427705)

  • 21. Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status.
    Furuta T; Shirai N; Sugimoto M; Nakamura A; Okudaira K; Kajimura M; Hishida A
    Aliment Pharmacol Ther; 2005 Jul; 22(1):67-74. PubMed ID: 15963082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
    Lee SB; Park SJ; Ryu JK; Lee JK; Kim HJ; Bae JS; Jung HS; Park SM
    Korean J Gastroenterol; 2003 Dec; 42(6):468-75. PubMed ID: 14695703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism.
    Hunfeld NG; Touw DJ; Mathot RA; van Schaik RH; Kuipers EJ
    Aliment Pharmacol Ther; 2012 Apr; 35(7):810-8. PubMed ID: 22324425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of CYP2C19 polymorphisms on exacerbating effect of rabeprazole in celecoxib-induced small bowel injury.
    Nuki Y; Umeno J; Washio E; Maehata Y; Hirano A; Miyazaki M; Kobayashi H; Kitazono T; Matsumoto T; Esaki M
    Aliment Pharmacol Ther; 2017 Aug; 46(3):331-336. PubMed ID: 28481007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers.
    Nishino M; Sugimoto M; Kodaira C; Yamade M; Shirai N; Ikuma M; Tanaka T; Sugimura H; Hishida A; Furuta T
    Dig Dis Sci; 2010 Jun; 55(6):1627-36. PubMed ID: 19672708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation.
    Yamano HO; Matsushita HO; Yanagiwara S
    J Gastroenterol Hepatol; 2008 Apr; 23(4):534-40. PubMed ID: 17725594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status.
    Sugimoto M; Furuta T; Shirai N; Ikuma M; Hishida A; Ishizaki T
    Clin Pharmacol Ther; 2006 Nov; 80(5):539-48. PubMed ID: 17112810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intragastric acidity during the first day following administration of low-dose proton pump inhibitors: a randomized crossover study.
    Hata S; Arai M; Maruoka D; Tanaka T; Matsumura T; Suzuki T; Nakagawa T; Katsuno T; Imazeki F; Yokosuka O
    Clin Res Hepatol Gastroenterol; 2013 Jun; 37(3):296-301. PubMed ID: 22959094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease].
    Sohn YH; Lee WS; Park CH; Joo YE; Kim HS; Choi SK; Rew JS; Kim SJ
    Korean J Gastroenterol; 2006 Sep; 48(3):162-71. PubMed ID: 17047431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism.
    Lou HY; Chang CC; Sheu MT; Chen YC; Ho HO
    Eur J Clin Pharmacol; 2009 Jan; 65(1):55-64. PubMed ID: 18751689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects.
    Warrington S; Baisley K; Boyce M; Tejura B; Morocutti A; Miller N
    Aliment Pharmacol Ther; 2002 Jul; 16(7):1301-7. PubMed ID: 12144580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Timing of Proton Pump Inhibitor Administration on Acid Suppression.
    Furuta K; Adachi K; Aimi M; Shimura S; Mikami H; Nishimura N; Ishimura N; Ishihara S; Naora K; Kinoshita Y
    Digestion; 2016; 93(2):111-20. PubMed ID: 26637113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19 genotype.
    Uotani T; Sugimoto M; Nishino M; Kodaira C; Yamade M; Sahara S; Yamada T; Osawa S; Sugimoto K; Tanaka T; Umemura K; Watanabe H; Miyajima H; Furuta T
    Clin Gastroenterol Hepatol; 2012 Aug; 10(8):879-885.e2. PubMed ID: 22542748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of different omeprazole dosing on gastric pH in non-variceal upper gastrointestinal bleeding: A randomized prospective study.
    Chwiesko A; Charkiewicz R; Niklinski J; Luczaj W; Skrzydlewska E; Milewski R; Baniukiewicz A; Wroblewski E; Rosolowski M; Dabrowski A
    J Dig Dis; 2016 Sep; 17(9):588-599. PubMed ID: 27518195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of rabeprazole (E3810), a novel proton pump inhibitor, on intragastric pH in healthy volunteers.
    Hongo M; Kimpara T; Moriyama S; Ohara S; Sone S; Tamura T; Asaki S; Toyota T
    Tohoku J Exp Med; 1998 Sep; 186(1):43-50. PubMed ID: 9915106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Helicobacter pylori eradication rates of standard 14-day quadruple treatment and novel modified 10-day, 12-day and 14-day sequential treatments.
    Sapmaz F; Kalkan IH; Güliter S; Atasoy P
    Eur J Intern Med; 2014 Mar; 25(3):224-9. PubMed ID: 24268371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
    Funck-Brentano C; Szymezak J; Steichen O; Ducint D; Molimard M; Remones V; Azizi M; Gaussem P
    Arch Cardiovasc Dis; 2013 Dec; 106(12):661-71. PubMed ID: 24246616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immediate acid-suppressing effects of ranitidine hydrochloride and rabeprazole sodium following initial administration and reintroduction: A randomized, cross-over study using wireless pH monitoring capsules.
    Ono S; Kato M; Ono Y; Imai A; Yoshida T; Shimizu Y; Asaka M
    J Gastroenterol Hepatol; 2009 Apr; 24(4):639-45. PubMed ID: 19032447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole.
    Furuta T; Kodaira C; Nishino M; Yamade M; Sugimoto M; Ikuma M; Hishida A; Watanabe H; Umemura K
    Aliment Pharmacol Ther; 2009 Aug; 30(3):294-300. PubMed ID: 19459830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study).
    Takeuchi T; Furuta T; Fujiwara Y; Sugimoto M; Kasugai K; Kusano M; Okada H; Suzuki T; Higuchi T; Kagami T; Uotani T; Yamade M; Sawada A; Tanaka F; Harada S; Ota K; Kojima Y; Murata M; Tamura Y; Funaki Y; Kawamura O; Okamoto Y; Fujimoto K; Higuchi K
    Aliment Pharmacol Ther; 2020 Mar; 51(5):534-543. PubMed ID: 31990424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.